Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

REGENERON PHARMACEUTICALS, INC. Director's Dealing 2012

Apr 30, 2012

29977_dirs_2012-04-30_993aaf78-9bf3-4b2e-9425-32d656b4e96c.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: REGENERON PHARMACEUTICALS INC (REGN)
CIK: 0000872589
Period of Report: 2012-04-27

Reporting Person: Van Plew Daniel P (SVP & General Mgr Industrial O)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2012-04-27 Common Stock M 30432.0 $20.9 Acquired 35216.0 Direct
2012-04-27 Common Stock F 4596.0 $138.36 Disposed 30620.0 Direct
2012-04-27 Common Stock F 11394.0 $138.36 Disposed 19226.0 Direct
2012-04-27 Common Stock M 4784.0 $20.9 Acquired 24010.0 Direct
2012-04-30 Common Stock S 1299.0 $135.94 Disposed 22711.0 Direct
2012-04-30 Common Stock S 13143.0 $136.42 Disposed 9568.0 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2012-04-27 Incentive Stock Option (right to buy) $20.9 M 4784.0 Disposed 2017-09-07 Common Stock (4784.0) Direct
2012-04-27 Non-Qualified Stock Option (right to buy) $20.9 M 30432.0 Disposed 2017-09-07 Common Stock (30432.0) Direct

Holdings (Non-Derivative)

Security Shares Ownership
Common Stock 1305.0 Indirect

Footnotes

F1: Represents volume-weighted average price of sales of 1,299 shares of Company stock on April 30, 2012 at prices ranging from $135.91 to $135.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 30, 2012 at each separate price.

F2: Represents volume-weighted average price of sales of 13,143 shares of Company stock on April 30, 2012 at prices ranging from $136.01 to $136.84. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 30, 2012 at each separate price.

F3: The stock option award (combined incentive stock option and non-qualified stock option) vests in four equal annual installments, commencing one year after the date of grant.

F4: Exercisable date, exercise date, exercise price, purchase price, sales price, and/or expiration date is/are not applicable in this case.